# APHINITY (NCT01358877)

> A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01358877
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Breast Cancer
- Interventions: 5-Fluorouracil; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Paclitaxel; Pertuzumab; Placebo; Trastuzumab
- Enrollment: 4804
- Primary outcome: Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
- Primary outcome: Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

## Commentary we found

- X threads: 50
- YouTube: 11
- Podcasts: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=aphinity-nct01358877

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01358877", "email": "<work email>"}; the inbox owner confirms by the emailed link.